Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth

Wood, N., Marshall, H., White, O.J., Holt, P.G. and McIntyre, P. (2014) Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth. Pediatric Infectious Disease Journal, 33 5: 511-517. doi:10.1097/INF.0000000000000246

Author Wood, N.
Marshall, H.
White, O.J.
Holt, P.G.
McIntyre, P.
Title Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth
Journal name Pediatric Infectious Disease Journal   Check publisher's open access policy
ISSN 1532-0987
Publication date 2014
Sub-type Article (original research)
DOI 10.1097/INF.0000000000000246
Open Access Status
Volume 33
Issue 5
Start page 511
End page 517
Total pages 7
Place of publication Philadelphia, PA, U.S.A.
Publisher Lippincott Williams and Wilkins
Collection year 2015
Language eng
Subject 2735 Pediatrics, Perinatology, and Child Health
2725 Infectious Diseases
2726 Microbiology (medical)
Abstract BACKGROUND:: In a previous study, we found that monovalent acellular pertussis (aP) vaccine at birth and 1 month achieves higher IgG antibody (Ab) levels to pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin by 8 weeks, when compared with controls. Here, we report antibody and cell-mediated immune responses to 4 years of age. METHODS:: IgG Ab to PT, filamentous hemagglutinin and pertactin, diphtheria (D) and tetanus (T) was measured in the 3 groups (aP vaccine at birth and 1 month, aP birth only and no aP) at 2 years of age and before and after DTaP-inactivated polio vaccine (DTaP-IPV) at 4 years of age. Cell-mediated immune responses to pertussis vaccine antigens were measured at 2 years of age. Adverse events following DTaP-IPV were recorded. RESULTS:: Of 74 subjects, 52 (70%) were available for follow up. Overall, 11 (21%) had detectable PT IgG at 2 years, decreasing to 10% before 4-year-old booster compared with 100% at 8 months of age. After the 4-year booster, pertussis antigen IgG levels were similar, but there was a trend to lower PT IgG levels in birth aP infants (geometric mean concentrations: 28.7 EI.U/mL) compared with controls (geometric mean concentrations: 53.6 EI.U/mL). The cytokine responses to pertussis antigen stimulation were higher in aP recipients at 2 years of age. There was no difference in injection site reactions among groups following the DTaP-IPV booster at 4 years of age. CONCLUSIONS:: In the longest reported follow-up of infants who received aP vaccine at birth, we found a trend to lower PT IgG antibodies post booster compared with receipt of first dose of aP-containing vaccine at 8 weeks of age. Short- and long-term antibody responses with and without prior maternal pertussis vaccination are crucial for further evaluation of this strategy for preventing severe early pertussis.
Keyword acellular pertussis vaccine
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
Queensland Children's Medical Research Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 20 May 2014, 02:26:17 EST by System User on behalf of School of Medicine